GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » Shiller PE Ratio

Avadel Pharmaceuticals (FRA:AWK) Shiller PE Ratio : (As of May. 01, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avadel Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Avadel Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Shiller PE Ratio Chart

Avadel Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avadel Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avadel Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Avadel Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Avadel Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Avadel Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.048/122.4391*122.4391
=-0.048

Current CPI (Dec. 2024) = 122.4391.

Avadel Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 0.249 99.975 0.305
201506 -0.374 100.573 -0.455
201509 -0.615 100.274 -0.751
201512 1.607 99.676 1.974
201603 -0.135 99.676 -0.166
201606 -0.427 101.072 -0.517
201609 -0.428 100.274 -0.523
201612 0.104 99.676 0.128
201703 0.570 100.374 0.695
201706 0.605 100.673 0.736
201709 0.436 100.474 0.531
201712 -0.203 100.075 -0.248
201803 -0.260 100.573 -0.317
201806 -0.077 101.072 -0.093
201809 -0.369 101.371 -0.446
201812 -1.503 100.773 -1.826
201903 -0.310 101.670 -0.373
201906 -0.204 102.168 -0.244
201909 -0.218 102.268 -0.261
201912 -0.063 102.068 -0.076
202003 -0.018 102.367 -0.022
202006 0.435 101.769 0.523
202009 -0.170 101.072 -0.206
202012 -0.156 101.072 -0.189
202103 -0.193 102.367 -0.231
202106 -0.274 103.364 -0.325
202109 -0.323 104.859 -0.377
202112 -0.336 106.653 -0.386
202203 -0.409 109.245 -0.458
202206 -1.012 112.779 -1.099
202209 -0.333 113.504 -0.359
202212 -0.415 115.436 -0.440
202303 -0.448 117.609 -0.466
202306 -0.766 119.662 -0.784
202309 -0.384 120.749 -0.389
202312 -0.266 120.749 -0.270
202403 -0.276 120.990 -0.279
202406 -0.130 122.318 -0.130
202409 -0.027 121.594 -0.027
202412 -0.048 122.439 -0.048

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avadel Pharmaceuticals  (FRA:AWK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Avadel Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.